Latest News About Colorectal Cancer

Here are the latest colorectal cancer news highlights from reputable sources:

• New KRAS-G12C–targeted therapy in colorectal cancer: A regimen combining adagrasib (Krazati) with cetuximab shown to shrink or eliminate tumors in advanced or certain localized settings. This approach has received FDA accelerated approval for KRAS-G12C–mutant colorectal cancer and is being explored in broader contexts, including rectal cancer and other KRAS-driven colon cancers [MSKCC news, 2026-03-04]. This marks a significant advance in targeted therapy for colorectal cancer, potentially reducing reliance on traditional chemotherapy in some patients [MSKCC news, 2026-03-04]. Source: Memorial Sloan Kettering Cancer Center press release.[1]

• Ongoing colorectal cancer trials and immunotherapy: Research continues into immunotherapy strategies and combination regimens for various molecular subtypes (including MMRd and HER2-positive tumors), with trial results published in high-impact journals and presented at major oncology meetings. These efforts aim to expand options beyond standard chemotherapy and radiation, and to personalize treatment based on genetic alterations [MSKCC, 2026-03-04; NEJM April 2025 results referenced in the MSK release].[1]

• Broad research and advocacy updates: National Cancer Institute and major cancer organizations regularly publish summaries of advances in screening, prevention, and treatment, including new regimens that improve survival and quality of life for colorectal cancer patients. These updates also emphasize access to trials and genetic risk assessment for high-risk families [NCI articles; Cancer.org updates; ACS awareness initiatives].[2][6]

• Public-facing resources and patient information: Cancer-focused organizations provide continually updated news libraries and press releases about trials, approvals, and caregiver resources, helping patients stay informed about emerging therapies and screening recommendations [WebMD news library; Colorectal Cancer Alliance updates].[4][5]

Illustrative example:

• A pivotal trial in colorectal cancer paired a targeted KRAS-G12C inhibitor with an EGFR inhibitor, producing tumor responses in a subset of patients who previously had limited options. While early, these results have driven regulatory and research interest, signaling a shift toward genotype-directed therapy in colorectal cancer [MSKCC press release, 2026-03-04].[1]

Notes:

• If you’d like, I can pull the latest headlines with direct links and summarize each study’s design, patient population, and key outcomes.
• For Prague or Czech-speaking audiences, I can tailor a concise briefing with regional trial centers and screening guidelines, if that’s helpful.